Continuous Infusion versus Double Bolus

From 1995 through 2002, we participated in four international randomized studies and one collaborative study with the University of Vermont in which pharmacological thrombolysis was employed with alteplase [tissue-type plasminogen activator (t-PA)] or tenecteplase [TNK-t-PA (TNK)]. In this chapter we summarize our experience with the cohorts of patients in all of these studies who were studied in the United Arab Emirates (UAE). The first of the studies was the Continuous Infusion versus Double Bolus of Alteplase (COBALT) study. The other three were Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT I, II, III) studies and a substudy in ASSENT II with the University of Vermont (4-8). The last study, a collaborative one with the University of Vermont, was the Enhanced Rapidity of RECanah-zation with Tenecteplase compared with Alteplase (ERRECTA) study, results of which have not yet been published. All of the patients participating in ERRECTA were patients in the UAE. 

The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction. N Engl J Med 1997 337 1127-1130. 

---